Description
Tirzep (Tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, a once-weekly subcutaneous injectable twincretin that simultaneously activates the GIP receptor (GIPR) with potency comparable to native GIP and the GLP-1 receptor (GLP-1R) to potentiate glucose-dependent insulin secretion from pancreatic beta cells, suppress inappropriate glucagon release from pancreatic alpha cells, slow gastric emptying to attenuate postprandial glucose excursions, and engage central satiety circuits in the hypothalamus, producing clinically meaningful reductions in both HbA1c and body weight that exceed those of any previously approved incretin-based agent.
Supplied as a subcutaneous injection in a pre-filled syringe, 1 pre-filled syringe per box, available in strengths of 2.5 mg, 5 mg, 7.5 mg, and 12.5 mg, and manufactured by ACI Limited, Bangladesh. Its active ingredient, tirzepatide INN, is a 39-amino acid acylated peptide with structural homology to native GIP, engineered to bind and activate both GIPR and GLP-1R within a single molecular entity, the first approved dual incretin receptor agonist (twincretin) in the antidiabetic drug class, structurally and mechanistically distinct from monoagonist GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) that activate only the GLP-1 receptor. The co-activation of GIPR by tirzepatide augments the GLP-1R-mediated glycemic and weight effects by engaging adipose tissue GIP receptors involved in lipid partitioning and by potentiating pancreatic beta cell responsiveness through synergistic cyclic adenosine monophosphate (cAMP) signaling from both receptor pathways simultaneously.
In the pivotal SURPASS-1 monotherapy trial (478 patients, 40 weeks), tirzepatide 5 mg achieved a mean HbA1c reduction of 1.87% from baseline versus 0.04% with placebo, with 87.4% of patients achieving HbA1c below 7.0% versus 19.9% with placebo, without hypoglycemia as monotherapy. In the SURPASS-2 head-to-head trial versus semaglutide 1 mg (1,879 patients, 40 weeks), tirzepatide 5 mg demonstrated superior HbA1c reduction of 1.94% versus 1.86% and superior body weight reduction of 7.6 kg versus 5.7 kg with semaglutide 1 mg, establishing tirzepatide as the most efficacious approved injectable antidiabetic agent studied against an active comparator in a prospective randomized trial.
At the 12.5 mg dose available in Tirzep, tirzepatide delivered a mean HbA1c reduction of 2.30% and mean body weight reduction of 11.2 kg in SURPASS-1 monotherapy, demonstrating the superior glycemic and weight outcomes achievable at higher therapeutic doses. Searching for Tirzep Tirzepatide? Mediaid Pharmacy lists this product across its diabetes medicines and Tirzepatide Medicines portfolios and ships it worldwide.
Basic Product Information of Tirzep (Tirzepatide)
| Brand Name | Tirzep (Tirzepatide) |
| Product Name | Tirzep |
| Generic Name | Tirzepatide INN |
| Drug Class | Dual GIP/GLP-1 Receptor Agonist; Twincretin; Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist; Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist; Dual Incretin Receptor Agonist; Once-Weekly Subcutaneous Injectable Antidiabetic Agent; Incretin Mimetic; Glucose-Dependent Insulin Secretion Potentiator; Glucagon Suppressor; Cardiometabolic Agent; Antiobesity Agent (Adjunct in T2DM) |
| Formulation | Subcutaneous Injection (Pre-filled Syringe) |
| Available Strengths | 2.5 mg, 5 mg, 7.5 mg, and 12.5 mg tirzepatide per pre-filled syringe |
| Available Pack Size | 1 pre-filled syringe per box |
| Recommended Dose & Administration | Initiation dose: 2.5 mg subcutaneously once weekly for 4 weeks. This is a tolerability initiation dose, not the therapeutic maintenance dose; it minimizes nausea and gastrointestinal adverse effects during treatment commencement. Step 1 (First Therapeutic Dose): Increase to 5 mg subcutaneously once weekly after completing 4 weeks at 2.5 mg. Maintain at 5 mg for a minimum of 4 weeks before considering further escalation. Step 2: If additional glycemic control is required and the patient tolerates 5 mg, increase to 7.5 mg subcutaneously once weekly after at least 4 weeks at 5 mg. Maintain at 7.5 mg for a minimum of 4 weeks before considering further escalation. Step 3 (Advanced Therapeutic Dose): If further glycemic control or body weight reduction is required and the patient tolerates 7.5 mg, increase to 12.5 mg subcutaneously once weekly after at least 4 weeks at 7.5 mg. The 12.5 mg strength is the maximum strength available in Tirzep pre-filled syringes by ACI Limited. If the prescribing endocrinologist determines that doses above 12.5 mg (such as 15 mg) are required, sourcing a higher-strength tirzepatide product should be discussed with the treating specialist. Injection sites: Administer subcutaneously into the abdomen (at least 5 cm from the navel), thigh, or upper arm; rotate injection sites with each weekly dose to reduce local injection site reactions. Tirzep may be injected at any time of day, with or without food. Missed dose: If a dose is missed and the next scheduled dose is more than 4 days away, administer the missed dose as soon as possible and resume the regular weekly schedule. If the next scheduled dose is 4 days or fewer away, skip the missed dose and continue with the next scheduled weekly injection. Do not administer two doses within 3 days of each other. Renal and hepatic impairment: No dose adjustment is required for mild to moderate renal impairment (eGFR 30 mL/min/1.73 m² or greater); use with caution in severe renal impairment. No dose adjustment required for hepatic impairment. Always confirm the dose, injection technique, and escalation schedule with the prescribing endocrinologist before initiating or adjusting Tirzep therapy. |
| Primary Indications | Type 2 Diabetes Mellitus (T2DM): As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, used as monotherapy or in combination with other antidiabetic agents (metformin, sulfonylurea, SGLT2 inhibitor) or basal insulin when existing therapy does not achieve adequate glycemic control. Tirzepatide is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. Each treatment decision must account for baseline HbA1c, body weight goals, cardiovascular risk, concomitant antidiabetic medications, renal function, and gastrointestinal tolerability. Always consult the full prescribing information and the treating endocrinologist or diabetologist before initiating or adjusting therapy. |
| Manufacturer | ACI Limited, Bangladesh |
| Country of Origin | Bangladesh |
| SKU | tirzepatide-tirzep |
| Registration | Bangladesh |
| Originator Reference Brand | Mounjaro® (tirzepatide injection, developed and marketed by Eli Lilly and Company; approved by the U.S. Food and Drug Administration on May 13, 2022, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus). Mounjaro® contains tirzepatide INN as the active pharmaceutical ingredient in the same dual GIP/GLP-1 receptor agonist (twincretin) drug class and is available at doses up to 15 mg. Tirzep is manufactured by ACI Limited in Bangladesh and is supplied through Mediaid Pharmacy for international procurement across doses of 2.5 mg, 5 mg, 7.5 mg, and 12.5 mg. |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze; discard Tirzep pre-filled syringes that have been frozen. If necessary, each pre-filled syringe may be stored unrefrigerated at room temperature up to 30°C (86°F) for a maximum of 21 days. Protect from light and direct heat. Keep in the original packaging until use. Keep out of the reach of children. Do not use after the expiry date printed on the carton and pre-filled syringe label. |
How Tirzep (Tirzepatide) Works: Dual GIP and GLP-1 Receptor Agonism and Twincretin Pharmacology in Type 2 Diabetes
Tirzepatide INN is a 39-amino acid acylated peptide that functions as a dual agonist at two distinct incretin hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). This dual receptor mechanism, the first of its kind among approved antidiabetic agents, earns tirzepatide the designation “twincretin.” Tirzep (Tirzepatide) simultaneously activates two complementary glucose-lowering and weight-reducing signaling pathways that monoagonist GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) cannot replicate.
GLP-1 is secreted by intestinal L cells in the distal ileum and colon following nutrient ingestion, stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion from pancreatic alpha cells, slowing gastric emptying to reduce postprandial glucose excursions, and activating hypothalamic and brainstem satiety circuits. GIP is secreted by K cells in the duodenum and proximal jejunum in response to fat and carbohydrate ingestion, potentiating glucose-dependent insulin secretion through a distinct cAMP signaling cascade in pancreatic beta cells and engaging adipose tissue GIPR-expressing cells involved in lipid partitioning and energy balance. In type 2 diabetes mellitus (T2DM), both incretin axes are functionally impaired: the GLP-1 response is markedly attenuated and the residual GIP response fails to elicit a normal insulin secretory response in the insulin-resistant beta cell.
This is precisely the dual incretin deficit that tirzepatide’s co-receptor engagement addresses by simultaneously reconstituting both GIP and GLP-1 signaling arms within a single molecular entity. Tirzep, manufactured by ACI Limited in Bangladesh, delivers tirzepatide INN across four pre-filled syringe strengths (2.5 mg, 5 mg, 7.5 mg, and 12.5 mg), supporting the full approved dose titration sequence from tolerability initiation through four consecutive escalation steps, enabling endocrinologists to achieve higher therapeutic doses within a single continuous product range without requiring a supplier change.
The structural basis of tirzepatide’s dual receptor activity lies in its peptide architecture: a 39-amino acid sequence with structural homology to native GIP at the N-terminus, optimized through amino acid substitutions for balanced GIPR and GLP-1R binding affinity, conjugated at lysine-26 to a C20 fatty diacid moiety via a gamma-glutamic acid-miniPEG linker. This modification confers high albumin binding exceeding 99%, protects the peptide from N-terminal DPP-4 cleavage that inactivates native GIP and GLP-1 within 1 to 2 minutes of portal entry, and provides an extended elimination half-life of approximately 5 days that supports once-weekly subcutaneous dosing.
Tirzepatide activates GIPR with potency approximately equivalent to native GIP and activates GLP-1R with approximately 5-fold lower potency than native GLP-1, yet produces GLP-1R-mediated pharmacological effects (insulin secretion, glucagon suppression, gastric emptying delay, appetite suppression, body weight reduction) that equal or exceed those of optimized GLP-1 monoagonists in head-to-head clinical trials. Critically, the clinical efficacy of tirzepatide is dose-dependent across the approved escalation range: in SURPASS-1 monotherapy (40 weeks), tirzepatide 12.5 mg—the highest strength available in Tirzep—achieved a mean HbA1c reduction of 2.30% and mean body weight reduction of 11.2 kg versus 0.04% and 0.7 kg with placebo, demonstrating meaningfully greater glycemic and weight outcomes at the higher doses enabled by the Tirzep four-strength range compared to products limited to lower doses.
Pharmacokinetically, following subcutaneous administration, tirzepatide reaches peak plasma concentration (Tmax) at approximately 8 to 72 hours, achieves steady-state concentrations by 4 weeks of once-weekly dosing, and is eliminated primarily via proteolytic degradation of the peptide backbone and fatty acid beta-oxidation, with no single dominant cytochrome P450 (CYP) metabolic pathway and no clinically relevant accumulation with weekly dosing across a broad range of renal and hepatic function. For the complete range of diabetes medicines at Mediaid Pharmacy, browse the full portfolio available for worldwide shipping.
Tirzep (Tirzepatide): Indications, Dosing, and Key Safety Information
| Approved Indications | Type 2 Diabetes Mellitus (T2DM): Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Tirzep (Tirzepatide) is used as monotherapy when other oral agents are not tolerated or are contraindicated, and as add-on combination therapy with metformin, sulfonylureas, SGLT2 inhibitors, or basal insulin when single-agent or existing combination therapy fails to achieve adequate HbA1c targets. Tirzepatide is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis. The treating endocrinologist determines appropriate candidacy, dose titration schedule, and combination regimen based on individual patient HbA1c targets, weight goals, cardiovascular risk, renal function, and gastrointestinal tolerability profile. |
| Dosing Schedule | Weeks 1–4 (Initiation): 2.5 mg subcutaneously once weekly. This is the tolerability initiation dose and not the therapeutic maintenance dose. Weeks 5 onward (Step 1 Therapeutic): 5 mg subcutaneously once weekly after completing 4 weeks at 2.5 mg; maintain for at least 4 weeks. Step 2 (if additional control required): 7.5 mg subcutaneously once weekly after at least 4 weeks at 5 mg; maintain for at least 4 weeks before any further escalation. Step 3 (Advanced Therapeutic Dose): 12.5 mg subcutaneously once weekly after at least 4 weeks at 7.5 mg; this is the maximum strength available in Tirzep pre-filled syringes by ACI Limited. If the prescribing endocrinologist determines that doses above 12.5 mg are required, a higher-strength tirzepatide formulation should be discussed with the treating specialist. Inject subcutaneously into the abdomen, thigh, or upper arm; rotate injection sites each week. Administer at any time of day, with or without meals. |
| Common Adverse Reactions | The most commonly reported adverse reactions with tirzepatide in the SURPASS Phase 3 clinical trial program are gastrointestinal: nausea (12 to 18% at 5 mg, increasing to approximately 22% at 12.5 mg), diarrhea (12 to 17%), vomiting (5 to 11%), and constipation (6 to 11%), predominantly occurring during dose initiation and escalation phases and generally transient. The stepwise dose escalation embedded in Tirzep’s dosing schedule—with mandatory 4-week intervals at each of the four strengths (2.5 mg, 5 mg, 7.5 mg, 12.5 mg)—is specifically designed to minimize gastrointestinal adverse events at each escalation step. Injection site reactions (erythema, pain, bruising) are reported in approximately 3 to 7% of patients. Hypoglycemia does not occur with Tirzep as monotherapy due to its strictly glucose-dependent insulin secretion mechanism; hypoglycemia risk increases when tirzepatide is combined with a sulfonylurea or basal insulin, and dose reduction of the sulfonylurea or insulin should be considered. Rare serious adverse reactions include acute pancreatitis (discontinue Tirzep immediately if suspected), severe hypersensitivity reactions including anaphylaxis and angioedema, and acute gallbladder disease (cholelithiasis, cholecystitis). Tirzep (Tirzepatide) carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity data; it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Always discuss the complete safety profile with the treating endocrinologist before initiating or continuing Tirzep therapy. |
| Drug Interactions | Oral medications requiring rapid absorption or with narrow therapeutic index: Tirzepatide delays gastric emptying and may reduce the peak plasma concentration (Cmax) and alter the time to peak concentration (Tmax) of concomitantly administered oral medications. Particular caution is warranted with narrow therapeutic index oral drugs such as warfarin, cyclosporine, and digoxin. Oral contraceptives: When initiating Tirzep or escalating the dose, gastric emptying delay may transiently reduce peak concentrations of oral contraceptives; switch to non-oral contraception or add a barrier method for 4 weeks after starting Tirzep and for 4 weeks after each dose escalation step. This interaction applies across all four Tirzep dose escalation steps. Warfarin and other vitamin K antagonists: Monitor INR more frequently when initiating or dose-escalating Tirzep due to the potential effect on warfarin absorption kinetics. Insulin secretagogues and basal insulin: Concomitant use with a sulfonylurea (glimepiride, glibenclamide) or basal insulin (insulin glargine, insulin detemir) increases hypoglycemia risk; consider reducing the sulfonylurea or insulin dose when adding Tirzep to existing antidiabetic therapy, particularly during escalation to higher doses (7.5 mg and 12.5 mg). Other GLP-1 receptor agonists: Do not combine Tirzep (Tirzepatide) with another GLP-1 receptor agonist (semaglutide, liraglutide, dulaglutide, exenatide) as additive receptor agonism provides no established additional glycemic benefit and compounds gastrointestinal adverse effects. |
| Contraindications | Tirzep (Tirzepatide) is contraindicated in: patients with a personal or family history of medullary thyroid carcinoma (MTC); patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); patients with known serious hypersensitivity to tirzepatide or any component of the Tirzep formulation (including anaphylaxis or angioedema). Tirzepatide is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. |
| Renal Impairment | No dose adjustment of Tirzep (Tirzepatide) is required for mild to moderate renal impairment (eGFR 30 mL/min/1.73 m² or greater). Use with caution in severe renal impairment (eGFR less than 30 mL/min/1.73 m²) due to limited clinical data; the predominantly non-renal elimination of tirzepatide means pharmacokinetic exposure is not substantially increased by renal impairment, but gastrointestinal adverse effects (nausea, vomiting, diarrhea) may precipitate dehydration and acute kidney injury in renally vulnerable patients, necessitating closer clinical monitoring, hydration counseling, and renal function assessment during dose initiation and each escalation step. This is particularly relevant for patients escalating to the higher Tirzep doses (7.5 mg and 12.5 mg), where gastrointestinal adverse effects may be more pronounced. Consult the treating endocrinologist and nephrologist for individualized guidance in patients with advanced chronic kidney disease. |
| Pregnancy & Lactation | Tirzep (Tirzepatide) is not recommended during pregnancy. Tirzepatide caused adverse embryo-fetal developmental effects in animal reproductive toxicity studies at clinically relevant exposures; adequate and well-controlled human data in pregnancy are not available. The risks of uncontrolled maternal hyperglycemia during pregnancy and of tirzepatide fetal exposure must be carefully weighed; insulin remains the preferred antidiabetic agent during pregnancy for type 2 diabetes mellitus. Women of childbearing potential should use effective contraception throughout Tirzep therapy; if pregnancy occurs or is planned, discontinue Tirzep and transition to insulin therapy immediately under endocrinologist guidance. Breastfeeding is not recommended during Tirzep treatment, as it is unknown whether tirzepatide is excreted in human breast milk; the risk to the nursing infant cannot be excluded. |
Who Should Use Tirzep (Tirzepatide)?
Tirzep (Tirzepatide) is indicated for adults with type 2 diabetes mellitus requiring improved glycemic control as an adjunct to diet and exercise, a patient population defined by progressive insulin secretory failure, marked GLP-1 and GIP response impairment, postprandial glucagon excess, and frequently co-occurring excess body weight. A defining clinical advantage of Tirzep by ACI Limited over competing tirzepatide products is its four-strength pre-filled syringe range (2.5 mg, 5 mg, 7.5 mg, 12.5 mg): endocrinologists can prescribe tirzepatide from tolerability initiation through four consecutive escalation steps including the advanced 12.5 mg therapeutic dose without requiring a change of product, supplier, or pharmacy inventory line. This breadth of dose coverage within a single ACI Limited product makes Tirzep particularly well-suited to long-term diabetes management programs and high-volume endocrinology centers managing diverse patient populations across multiple glycemic and weight-loss targets.
First, adults with type 2 diabetes requiring substantial HbA1c reduction represent the primary population for Tirzep therapy. Those with baseline HbA1c above 8.5%, or requiring reductions exceeding 1.5% to reach individual targets, benefit most from escalating to higher tirzepatide doses. In SURPASS-1 monotherapy (40 weeks), tirzepatide 12.5 mg achieved a mean HbA1c reduction of 2.30% versus 0.04% with placebo, with 90.1% of patients reaching HbA1c below 7.0% outcomes achievable in clinical practice with Tirzep without sourcing a separate higher-strength product.
Second, adults with type 2 diabetes and significant overweight or obesity for whom concurrent body weight reduction is a clinical priority are especially well served by escalation to the 7.5 mg and 12.5 mg Tirzep strengths. In SURPASS-1, tirzepatide 12.5 mg produced mean body weight reduction of 11.2 kg versus 0.7 kg with placebo over 40 weeks, a result that significantly exceeds the weight outcomes achievable at the 5 mg dose and is only accessible in Tirzep without product substitution.
Third, adults requiring injectable antidiabetic therapy escalation beyond oral agents, including those in whom GLP-1 monoagonist therapy (semaglutide, liraglutide) has produced suboptimal glycemic or weight outcomes, benefit from tirzepatide’s additional GIPR co-agonism a mechanistically distinct pathway not activated by any approved monoagonist.
Fourth, adults with type 2 diabetes for whom minimizing hypoglycemia risk is a clinical priority benefit from tirzepatide’s strictly glucose-dependent insulin secretion mechanism, which produced no hypoglycemia as monotherapy at any dose across the SURPASS trial program. Endocrinology centers and diabetes specialist clinics co-sourcing Tirzep alongside other specialty injectable antidiabetic medicines can browse the Mediaid Pharmacy diabetes medicine collection for the full selection available for international delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Tirzep (Tirzepatide)
Mediaid Pharmacy is a Dhaka-based supplier of specialty diabetes, endocrinology, and metabolic medicines with worldwide shipping to patients, diabetes specialist centers, endocrinology clinics, hospital pharmacy departments, and international distributors across all regions. Tirzep (Tirzepatide), manufactured by ACI Limited in Bangladesh, is supplied as a subcutaneous injection in pre-filled syringes, available in 2.5 mg, 5 mg, 7.5 mg, and 12.5 mg strengths, 1 pre-filled syringe per box, with pricing quotations, stock confirmation, full product documentation, and end-to-end international delivery tracking for every order.
The four-strength range of Tirzep by ACI Limited covering tolerability initiation (2.5 mg), first-step therapeutic dosing (5 mg), second-step escalation (7.5 mg), and advanced therapeutic dosing (12.5 mg) provides diabetes programs and endocrinology centers with the flexibility to support the majority of their patient population’s dose escalation needs from a single consolidated product, reducing procurement complexity, supplier management overhead, and the patient-facing disruption of switching products mid-treatment course.
Diabetes specialist centers managing type 2 diabetes requiring superior glycemic and weight-reduction efficacy, endocrinology programs requiring a dual GIP/GLP-1 receptor agonist with the full SURPASS Phase 3 clinical evidence base at multiple doses, hospital pharmacy departments co-sourcing injectable antidiabetic agents for inpatient or outpatient use, international distributors, and individual patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries regarding Tirzep Tirzepatide stock availability, current pricing by strength, and international delivery timelines.
Procurement teams co-sourcing Tirzep with other specialty diabetes medicines can browse the complete Mediaid Pharmacy buy diabetes medicines online catalog and the ACI Limited medicines portfolio before requesting a consolidated quotation.
Why Choose Tirzep (Tirzepatide) from Mediaid Pharmacy?
Tirzep (Tirzepatide) delivers the most clinically documented HbA1c reduction and body weight reduction among approved injectable antidiabetic agents, a differentiation established in the SURPASS clinical trial program through a unique twincretin mechanism of simultaneous GIP and GLP-1 receptor co-activation that no single-receptor GLP-1 agonist, DPP-4 inhibitor, SGLT2 inhibitor, or insulin class member can replicate in a single weekly injection. In SURPASS-2 (1,879 adults with type 2 diabetes, 40 weeks), tirzepatide 5 mg produced mean HbA1c reduction of 1.94% versus 1.86% with semaglutide 1 mg, and mean body weight reduction of 7.6 kg versus 5.7 kg with semaglutide 1 mg, with higher tirzepatide doses achieving statistically significant further superiority (p<0.001 for both endpoints).
Tirzep’s four-strength pre-filled syringe range (2.5 mg, 5 mg, 7.5 mg, 12.5 mg), manufactured by ACI Limited in Bangladesh, represents the broadest dose coverage available among Bangladeshi-manufactured tirzepatide products at Mediaid Pharmacy. Endocrinologists managing patients who require escalation to the advanced 12.5 mg therapeutic dose a dose producing mean HbA1c reduction of 2.30% and mean body weight reduction of 11.2 kg in SURPASS-1 monotherapy can prescribe Tirzep without sourcing a different product at any stage of the escalation schedule from initiation through 12.5 mg.
From a tolerability architecture perspective, the four-step escalation schedule embedded in Tirzep 2.5 mg for 4 weeks, then 5 mg for ≥4 weeks, then 7.5 mg for ≥4 weeks, then 12.5 mg provides the most gradual dose escalation ramp of any tirzepatide product range available at Mediaid Pharmacy, supporting superior gastrointestinal tolerability at each step and reducing adverse event-related treatment discontinuation in patients requiring advanced doses.
The absence of hypoglycemia as monotherapy, a direct consequence of tirzepatide’s glucose-dependent insulin secretion mechanism, applies across all four Tirzep strengths including 12.5 mg, meaning Tirzep can be initiated and escalated without hypoglycemia monitoring protocols beyond standard diabetic care at any dose within the product range.
From a dosing convenience standpoint, the once-weekly subcutaneous injection schedule eliminates the daily injection burden of liraglutide and the daily oral medication adherence requirement of DPP-4 inhibitors and SGLT2 inhibitors, supporting high adherence profiles in working-age patients, elderly patients, and all populations who benefit from weekly rather than daily medication routines. To source the full range of ACI Limited medicines at Mediaid Pharmacy and the complete selection of tirzepatide injection products available for worldwide shipping, browse both portfolios and contact the team for a personalized quotation by strength and quantity.
Frequently Asked Questions About Tirzep (Tirzepatide)
What is Tirzep (Tirzepatide) used for?
Tirzep (Tirzepatide) is a dual GIP and GLP-1 receptor agonist, a twincretin, used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Administered once weekly as a subcutaneous injection, Tirzep is used as monotherapy when metformin or other oral agents are not tolerated or are contraindicated, and as add-on combination therapy with metformin, sulfonylureas, SGLT2 inhibitors, or basal insulin when existing treatment fails to achieve adequate HbA1c control. Tirzep (Tirzepatide) works by simultaneously activating the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R), stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing inappropriate glucagon release, slowing gastric emptying to reduce postprandial glucose excursions, and engaging central satiety pathways to reduce appetite and body weight. The originator brand for tirzepatide is Mounjaro® (Eli Lilly and Company, FDA-approved May 13, 2022 for adults with T2DM). Tirzep, manufactured by ACI Limited in Bangladesh, is available in 2.5 mg, 5 mg, 7.5 mg, and 12.5 mg pre-filled syringes through Mediaid Pharmacy with worldwide shipping to patients, diabetes specialist centers, and endocrinology clinics globally.
What is the generic name of Tirzep?
The generic name of Tirzep is tirzepatide INN. Tirzep is the brand name registered by ACI Limited for tirzepatide manufactured in Bangladesh. Tirzep is formulated as a subcutaneous injection in pre-filled syringes, available in 2.5 mg, 5 mg, 7.5 mg, and 12.5 mg strengths, supplied as 1 pre-filled syringe per box, supporting the approved once-weekly dosing schedule from tolerability initiation at 2.5 mg through three consecutive therapeutic escalation steps up to 12.5 mg as directed by the treating endocrinologist. The originator reference brand is Mounjaro® (Eli Lilly and Company). Mediaid Pharmacy distributes Tirzep globally with worldwide shipping to patients, diabetes centers, endocrinology clinics, and hospital pharmacy departments.
What is the difference between Tirzep (Tirzepatide) and Mounjaro® (Tirzepatide)?
Tirzep and Mounjaro® both contain tirzepatide INN as the active pharmaceutical ingredient and share the same dual GIP/GLP-1 receptor agonist (twincretin) mechanism of action for type 2 diabetes mellitus. Mounjaro® is the originator brand developed and marketed by Eli Lilly and Company, approved by the FDA on May 13, 2022, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and is available in six doses up to 15 mg. Tirzep is manufactured by ACI Limited in Bangladesh and is supplied in pre-filled syringes in 2.5 mg, 5 mg, 7.5 mg, and 12.5 mg strengths, 1 pre-filled syringe per box, covering four of the six approved tirzepatide escalation doses and available through Mediaid Pharmacy for international procurement by specialist diabetes centers and patients in regions where Mounjaro® may be unavailable or cost-prohibitive. For the full range of buy tirzepatide online at Mediaid Pharmacy, browse the complete collection.
How is Tirzep (Tirzepatide) administered?
Tirzep (Tirzepatide) is administered once weekly as a subcutaneous injection using the pre-filled syringe. Recommended injection sites are the abdomen (at least 5 cm from the navel), the thigh, or the upper arm; rotate injection sites with each weekly administration to minimize local injection site reactions such as erythema, bruising, and pain. Tirzep may be administered at any time of day, independently of meals. The approved initiation schedule begins with 2.5 mg once weekly for 4 weeks, followed by 5 mg once weekly for at least 4 weeks (Step 1), then 7.5 mg once weekly for at least 4 weeks if further escalation is required (Step 2), and finally 12.5 mg once weekly as the maximum strength available in Tirzep (Step 3), advanced only under prescriber guidance. If a dose is missed and the next scheduled dose is more than 4 days away, administer the missed dose as soon as possible and resume the regular weekly schedule. If the next scheduled dose is 4 days or fewer away, skip the missed dose and continue with the next scheduled weekly injection; never administer two doses within 3 days of each other. Store Tirzep pre-filled syringes refrigerated at 2°C to 8°C until use. Always confirm injection technique, dose, and escalation timing with the prescribing endocrinologist before commencing Tirzep therapy.
What are the available strengths of Tirzep Tirzepatide?
Tirzep (Tirzepatide) manufactured by ACI Limited is available in four strengths: 2.5 mg, 5 mg, 7.5 mg, and 12.5 mg pre-filled syringes, supplied as 1 pre-filled syringe per box. The 2.5 mg strength is the tolerability initiation dose; the 5 mg strength is the first therapeutic maintenance dose; the 7.5 mg strength is the second escalation step; and the 12.5 mg strength is the advanced therapeutic dose and the maximum strength available in the Tirzep product range. If the treating endocrinologist determines that doses above 12.5 mg are required, a prescription for a higher-strength tirzepatide formulation should be obtained and discussed with the treating specialist. For ordering information and stock availability by strength, contact Mediaid Pharmacy at +8801773428128 or email info@mediaidpharmacy.com.
What are the side effects of Tirzep (Tirzepatide)?
The most common side effects of Tirzep (Tirzepatide) are gastrointestinal: nausea (12 to 18% at 5 mg, approximately 22% at 12.5 mg), diarrhea (12 to 17%), vomiting (5 to 11%), and constipation (6 to 11%), predominantly occurring during dose initiation and escalation and generally transient. The four-step escalation schedule in Tirzep with mandatory 4-week intervals between dose increases is specifically designed to allow gastrointestinal adaptation at each dose step before advancing further. Injection site reactions (erythema, bruising, pain) are reported in approximately 3 to 7% of patients; rotating injection sites reduces their incidence. Hypoglycemia does not occur with Tirzep as monotherapy at any dose; hypoglycemia risk increases when Tirzep is combined with a sulfonylurea or basal insulin, particularly at higher doses, and dose reduction of those agents should be considered. Rare but serious adverse reactions include acute pancreatitis (discontinue Tirzep immediately if pancreatitis is suspected) and severe hypersensitivity reactions including anaphylaxis and angioedema. Tirzep carries a boxed warning for thyroid C-cell tumors; instruct patients to report any neck masses, hoarseness, persistent dysphagia, or dysphonia. Always discuss the full safety profile with the treating endocrinologist before and throughout Tirzep treatment, particularly when escalating to the 7.5 mg and 12.5 mg doses.
Does Tirzep (Tirzepatide) cause weight loss?
Yes. Tirzep (Tirzepatide) produces clinically meaningful and dose-dependent body weight reductions in adults with type 2 diabetes, driven by its dual GIP and GLP-1 receptor agonism acting on hypothalamic satiety circuits to reduce appetite, gastric emptying delay reducing caloric absorption rate, and adipose tissue GIPR engagement modulating energy partitioning. In SURPASS-1 monotherapy (40 weeks), tirzepatide 5 mg produced mean body weight reduction of 7.0 kg; tirzepatide 7.5 mg produced mean reduction of 8.7 kg; and tirzepatide 12.5 mg the maximum strength available in Tirzep produced mean body weight reduction of 11.2 kg, all versus 0.7 kg with placebo. The dose-dependent weight reduction accessible through Tirzep’s four-strength range allows the treating endocrinologist to titrate both glycemic and weight outcomes simultaneously by advancing through the escalation steps appropriate to each patient’s clinical profile and tolerability. For the full range of diabetes medicines at Mediaid Pharmacy available with worldwide shipping, browse the complete portfolio.
How does Tirzep (Tirzepatide) compare to semaglutide for type 2 diabetes?
Tirzep (Tirzepatide) and semaglutide (originator brand: Ozempic®) are both once-weekly subcutaneous injectable antidiabetic agents, but they act through fundamentally different receptor mechanisms. Semaglutide is a monoagonist GLP-1 receptor agonist that activates only the GLP-1R. Tirzepatide is a dual GIP/GLP-1 receptor agonist (twincretin) that simultaneously activates both the GIPR and GLP-1R, adding an incretin signaling arm that semaglutide does not engage. In the SURPASS-2 head-to-head trial (1,879 adults with T2DM, 40 weeks), tirzepatide 5 mg achieved 1.94% HbA1c reduction and 7.6 kg weight loss versus 1.86% and 5.7 kg with semaglutide 1 mg, with superiority increasing at higher tirzepatide doses. Tirzep’s availability across four pre-filled syringe strengths (2.5 mg, 5 mg, 7.5 mg, 12.5 mg) from ACI Limited allows endocrinologists to prescribe tirzepatide at the doses where this clinical advantage over semaglutide was most definitively established in prospective randomized trials, without sourcing a separate product at any escalation step. The full selection of tirzepatide medicines at Mediaid Pharmacy is available for worldwide shipping; contact the team for pricing by strength and stock availability.
Can I order Tirzep (Tirzepatide) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies ACI Limited Tirzep (Tirzepatide) pre-filled syringes, available in 2.5 mg, 5 mg, 7.5 mg, and 12.5 mg strengths, to patients, diabetes specialist centers, endocrinology clinics, hospital pharmacy departments, and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing by strength, current stock availability, and international delivery details for your country.
Order Tirzep (Tirzepatide) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com




Reviews
There are no reviews yet.